Deepak Shukla Selected Research

Eye Infections

4/2022	Safety, efficacy and delivery of multiple nucleoside analogs via drug encapsulated carbon (DECON) based sustained drug release platform.
12/2021	Heparanase-Induced Activation of AKT Stabilizes β-Catenin and Modulates Wnt/β-Catenin Signaling during Herpes Simplex Virus 1 Infection.
1/2018	An off-target effect of BX795 blocks herpes simplex virus type 1 infection of the eye.
12/2017	Targeting Herpes Simplex Virus-1 gD by a DNA Aptamer Can Be an Effective New Strategy to Curb Viral Infection.
9/2013	An investigative peptide-acyclovir combination to control herpes simplex virus type 1 ocular infection.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Deepak Shukla Research Topics

Disease

68	Infections 12/2022 - 10/2002
21	Herpes Simplex 04/2022 - 10/2002
16	Virus Diseases (Viral Diseases) 04/2022 - 04/2011
7	Inflammation (Inflammations) 12/2021 - 10/2004
5	Eye Infections 04/2022 - 09/2013
5	Neoplasms (Cancer) 12/2021 - 08/2006
4	COVID-19 09/2022 - 06/2020
3	Herpesviridae Infections (Herpesvirus Infection) 04/2022 - 12/2008
3	Disease Progression 01/2022 - 01/2021
3	Wounds and Injuries (Trauma) 01/2021 - 01/2017
3	Keratitis 01/2021 - 02/2015
2	Cytokine Release Syndrome 01/2022 - 01/2022
2	Herpes Genitalis (Genital Herpes) 01/2019 - 01/2016
2	Latent Infection 01/2019 - 04/2013
1	Osteonecrosis (Kienbock's Disease) 03/2022
1	Periapical Periodontitis (Apical Periodontitis) 01/2022
1	Periodontitis 01/2022
1	Neurodegenerative Diseases (Neurodegenerative Disease) 12/2021
1	Neoplasm Metastasis (Metastasis) 03/2021
1	Corneal Opacity 01/2021
1	Herpetic Keratitis 10/2019
1	Pathologic Processes 02/2019
1	Melanoma (Melanoma, Malignant) 10/2018
1	Cytomegalovirus Infections (Inclusion Disease) 05/2015
1	Gastric Outlet Obstruction 10/2014
1	Multiple Sclerosis 04/2013
1	Iritis 04/2013

Drug/Important Bio-Agent (IBA)

17	Antiviral Agents (Antivirals)IBA 04/2022 - 08/2010
17	Proteins (Proteins, Gene)FDA Link 01/2022 - 10/2004
12	Heparitin Sulfate (Heparan Sulfate)IBA 01/2020 - 09/2005
9	Peptides (Polypeptides)IBA 10/2021 - 07/2011
8	CytokinesIBA 01/2022 - 04/2013
8	NectinsIBA 04/2013 - 10/2004
7	BX795IBA 04/2022 - 01/2018
7	heparanaseIBA 12/2021 - 04/2015
6	HCEIBA 12/2022 - 11/2010
6	VaccinesIBA 09/2022 - 04/2013
6	Acyclovir (Aciclovir)FDA LinkGeneric 04/2022 - 09/2013
6	Glycoproteins (Glycoprotein)IBA 02/2019 - 10/2002
5	EnzymesIBA 01/2021 - 11/2014
4	NucleosidesIBA 04/2022 - 06/2016
4	Zinc Oxide FDA Link 01/2019 - 12/2012
3	Biological ProductsIBA 12/2021 - 10/2002
3	DNA (Deoxyribonucleic Acid)IBA 03/2021 - 04/2015
3	Protein Isoforms (Isoforms)IBA 11/2014 - 10/2002
3	Cytochalasin DIBA 01/2013 - 08/2008
2	Liposomes (Liposome)IBA 12/2022 - 01/2016
2	CarbonIBA 04/2022 - 01/2019
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 12/2020 - 01/2019
2	Pharmaceutical PreparationsIBA 12/2020 - 01/2019
2	Syndecan-1 (Syndecan 1)IBA 01/2020 - 04/2011
2	MicroRNAs (MicroRNA)IBA 05/2018 - 01/2018
1	BBV152 COVID-19 vaccineIBA 09/2022
1	COVID-19 VaccinesIBA 09/2022
1	ChAdOx1 nCoV-19IBA 09/2022
1	2-benzyl-3-formylpropanoic acid (BFP)IBA 03/2022
1	NexusIBA 01/2022
1	Complement System Proteins (Complement)IBA 01/2022
1	Complement Inactivating AgentsIBA 01/2022
1	compstatinIBA 01/2022
1	CateninsIBA 12/2021
1	CholesterolIBA 12/2021
1	Antimicrobial PeptidesIBA 12/2021
1	HistatinsIBA 12/2021
1	sigma-2 receptorIBA 12/2021
1	TOR Serine-Threonine KinasesIBA 10/2021
1	Mechanistic Target of Rapamycin Complex 2IBA 10/2021
1	OligonucleotidesIBA 10/2021
1	Viral ProteinsIBA 10/2021
1	Virus ReceptorsIBA 01/2021
1	4-phenylbutyric acid (Buphenyl)FDA Link 12/2020
1	Carboxylic AcidsIBA 11/2020
1	PolymersIBA 11/2020
1	Virulence Factors (Pathogenicity Factors)IBA 01/2020
1	Metalloproteases (Metalloproteinases)IBA 01/2020
1	Matrix Metalloproteinases (MMPs)IBA 01/2020
1	ProdigiosinIBA 01/2020
1	Cell Surface ReceptorsIBA 02/2019
1	Cathepsin LIBA 12/2018
1	Enzyme Precursors (Zymogens)IBA 12/2018
1	matrigelIBA 10/2018
1	dimemorfan (AT 17)IBA 10/2018
1	Phosphotransferases (Kinase)IBA 01/2018
1	A-Form DNA (A-DNA)IBA 12/2017
1	Nucleotide AptamersIBA 12/2017
1	Glycoside Hydrolases (Endoglycosidases)IBA 09/2017
1	OxidesIBA 01/2017
1	MetalsIBA 01/2017
1	GalactosidasesIBA 01/2017
1	Anti-Infective Agents (Microbicides)IBA 01/2016
1	NF-kappa B (NF-kB)IBA 04/2015
1	Semaphorins (Semaphorin)IBA 02/2015
1	Capecitabine (Xeloda)FDA Link 10/2014
1	Myosin-Light-Chain KinaseIBA 01/2014
1	Nucleic Acid Synthesis InhibitorsIBA 05/2013

Therapy/Procedure

18	Therapeutics 01/2022 - 01/2012
2	Immunomodulation 12/2021 - 01/2021
2	Contact Lenses 01/2021 - 01/2016
1	Duration of Therapy 01/2019
1	Oncolytic Virotherapy 10/2018